A A Fox - JoVE Visualize

Showing results (371-380 of 491) with videos related to

Pageof 50

Sort By:

Circulation|June 5, 2014

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.

Journal of the American Heart Association|September 27, 2021

Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.

Journal of the American College of Cardiology|March 16, 2018

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS TrialSonia S Anand, Francois Caron, John W Eikelboom, et al.

European Heart Journal. Acute Cardiovascular Care|February 25, 2014

Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patientsGaetano M De Ferrari, Keith A A Fox, Jennifer A White, et al.

Circulation|February 21, 2014

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.

European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018

Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.

European Journal of Preventive Cardiology|August 31, 2021

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trialsSonia S Anand, Will Hiatt, Leanne Dyal, et al.

Open Heart|July 2, 2024

Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AFJelle C L Himmelreich, Saverio Virdone, John Camm, et al.

American Heart Journal|September 21, 2015

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.

American Heart Journal|December 19, 2015

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trialStephen J Nicholls, A Michael Lincoff, Philip J Barter, et al.

Pageof 50

Showing results (371-380 of 491) with videos related to

Sort By:

Pageof 50

Circulation|June 5, 2014

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.

Journal of the American Heart Association|September 27, 2021

Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.

Journal of the American College of Cardiology|March 16, 2018

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS TrialSonia S Anand, Francois Caron, John W Eikelboom, et al.

European Heart Journal. Acute Cardiovascular Care|February 25, 2014

Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patientsGaetano M De Ferrari, Keith A A Fox, Jennifer A White, et al.

Circulation|February 21, 2014

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.

European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018

Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.

European Journal of Preventive Cardiology|August 31, 2021

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trialsSonia S Anand, Will Hiatt, Leanne Dyal, et al.

Open Heart|July 2, 2024

Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AFJelle C L Himmelreich, Saverio Virdone, John Camm, et al.

American Heart Journal|September 21, 2015

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.

American Heart Journal|December 19, 2015

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trialStephen J Nicholls, A Michael Lincoff, Philip J Barter, et al.

Pageof 50